Healthcare Builders
Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. Exits include current and former a16z portfolio companies which have been acquired as well as companies which have undergone an initial public offering or direct public offering of shares. Certain publicly traded companies on this list may still be held in Andreessen Horowitz funds. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Excluded from this list are investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets. Further, the list of investments is updated monthly and as such may not reflect most recent a16z investments. Past results of Andreessen Horowitz’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results.
Themes in Health
-
Protecting the Golden Age of Medicine with John Crowley New
John Crowley, President and CEO of Biotechnology Innovation Organization (BIO), joins Jorge Conde, general partner at a16z Bio + Health.
-
A Fatal Inheritance with Lawrence Ingrassia
Lawrence Ingrassia, author and journalist, joins Vineeta Agarwala, general partner, and Kris Tatiossian, editorial lead at a16z Bio + Health.
-
Network Medicine with Jonathan Swerdlin and Mark Hyman
Jonathan Swerdlin, cofounder and CEO, and Mark Hyman, MD, cofounder and Chief Medical Officer of Function Health join Vijay Pande, general partner, and Daisy Wolf, investment partner of a16z Bio + Health.
-
Regulation as a Catalyst with Jonathan Bush and Chris Severn
Jonathan Bush, founder and CEO of Zus Health, and Chris Severn, cofounder and CEO of Turquoise Health, join Julie Yoo, general partner, and Colin Rom, head of public policy for a16z Bio + Health.
-
Investing in Function Health
Recently, we invested in Function Health, a company that embodies the vision and excitement we had when writing those theses. The one piece we underestimated is the current state of latent demand among consumers for a new approach to healthcare and longevity.
-
Investing in knownwell
This medical home is exactly what knownwell is building – and scaling. Through a hybrid virtual and in-person care model, knownwell offers both primary care as well as longitudinal specialty care, inclusive of weight management, diabetes care, medication (and side effect) management, multi-disciplinary nutritional counseling, and behavioral health services.
-
How We Live Longer
The most impactful way to fix healthcare is through improving the consumer experience, which has been largely ignored to date. In today’s modern world where you can order groceries, buy flight tickets, and wire money from your phone, taking care of yourself and navigating the healthcare system remains impossibly hard.
-
The Transformative Power of AI in Science with Pushmeet Kohli
In this episode, originally recorded for the a16z Podcast, host Steph Smith interviews Pushmeet Kohli, DeepMind's VP of Research focused on AI for science. They are joined by a16z Bio + Health founding partner Vijay Pand...
-
The Science and Supply of GLP-1s with Chronis Manolis
Chronis Manolis, SVP and Chief Pharmacy Officer of UPMC Health Plan, joins Julie Yoo, general partner, Daisy Wolf, investment partner, and Will Shrank, venture partner, of a16z Bio + Health.
-
The Science and Supply of GLP-1s with Brooke Boyarsky Pratt
Brooke Boyarsky Pratt, founder and CEO of knownwell, joins Vineeta Agarwala, general partner at a16z Bio + Health.
-
Investing in Valar Labs
There is perhaps nowhere more exciting or impactful to build such tools than in healthcare—where progress is often so constrained by human expertise. Valar Labs is taking on exactly this challenge, and bringing AI into the toolbox for better cancer care.
-
The Science and Supply of GLP-1s with Carolyn Jasik
As Ozempic, Wegovy, Mounjaro, and Zepbound capture the healthcare spotlight, we’ve developed a series of episodes that go beyond the headlines and take you into conversations with the specialists. Our first guest is Carolyn Jasik, MD, Chief Medical Officer at Omada Health.
-
Intersection of Biotech x High Tech with Vineeta Agarwala
Vineeta Agarwala, MD, PhD, joins Luke Timmerman's The Long Run podcast on stage at the Life Science Innovation Northwest Conference.
-
AI + a16z
The stakes are high. The opportunities are profound. From the creation of new medicines to bolstering national defense, this is our vision for the AI-enabled future.
-
AI in Pharmaceutical R&D with Kim Branson
Kim Branson, PhD, SVP and Global Head of AI and Machine Learning for GSK, joins Vijay Pande, founding partner at a16z Bio + Health. Together, they talk about how AI has improved drug discovery and development, as Kim walks through all the ways AI can be deployed in the lab.
-
Can AI Advance Science? DeepMind’s VP of Science Weighs In
In recent years, the AI landscape has seen huge advancements, from the release of Dall-E 2 in April 2022 to the emergence of AI music and video models in early 2024. While creative tools often steal the spotlight, AlphaF...
-
Longevity as a Health Asset with Tom Hale
Tom Hale, CEO of ŌURA, joins Vijay Pande, founding partner, and Daisy Wolf, investment partner at a16z Bio + Health.
-
The Power of Drug Discovery with Philip Tagari
Philip Tagari, Chief Scientific Officer of insitro, joins Vijay Pande, founding general partner at a16z Bio + Health.
-
AI-Enabled Continuity of Care with Ed and Todd Park
Vijay Pande, founding general partner of a16z Bio + Health, chats with the builders (and siblings) behind Devoted Health, Ed and Todd Park.
-
Grand Challenges in Healthcare AI with Vijay Pande and Julie Yoo
Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to talk through the grand challenges facing healthcare AI today.
-
Behind the Buy: Payors and Providers on AI Adoption
This episode features interviews with payor and provider leaders about what they’re seeing and how they’re thinking about AI. Guided by Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, you'll hear from the executives about how they're utilizing AI, the KPIs they use to gauge effectiveness, and what they consider to be a good partnership.
-
Biotech Revolution with Software Engineering Daily
Vijay Pande, founding general partner at a16z Bio + Health, joins the Software Engineering Daily podcast to talk about innovation in biotech and healthcare, the biotech startup landscape, the impact of AI, and much more.
-
Dark Genome Hunting with Rosana Kapeller and Marty Taylor
Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.
-
DNA as Data Storage with Vijay Pande
Vijay Pande, founding partner of a16z Bio + Health, dives deep with a16z Podcast host Steph Smith into the potential of DNA as a data storage mechanism.
-
The Most Interesting Healthcare Companies You’ve Never Heard Of with Julie Klapstein
Julie Klapstein, founding CEO of Availity, long-time healthcare executive, and a16z Bio + Health's newest advisory partner, joins Julie Yoo, general partner at a16z Bio + Health.
-
CRISPR by Design with Benjamin Oakes
Scribe Therapeutics cofounder and CEO Ben Oakes joins a16z Bio + Health founding general partner Vijay Pande.
-
Virtual Data Rooms: The Unsung Hero of Biotech Financing
The biotech industry is built on one of the cleanest go-to-market strategies in existence: if you make a safe drug that really works, patients are likely to receive it and payors are likely to pay for it. But how can biotech teams effectively communicate to investors and partners how they will, with each round of financing, incrementally reduce the risks of discovering and developing successful new drugs?
-
Metrics for a Complex Machine with Josh Clemente
Josh Clemente, cofounder and president of Levels, joins Vijay Pande, founding general partner, and Daisy Wolf, investment partner at a16z Bio + Health.
-
Transitioning from Gymnast to Investor with Aly Raisman
Former gymnast and current investor Aly Raisman joins general partner Julie Yoo and investment partner Daisy Wolf of a16z Bio + Health.
-
Finding PMF in Healthcare (After Tasting it Elsewhere) with Eren Bali and Max Cohen
Max Cohen, cofounder and CEO of Sprinter Health, and Eren Bali, founder and CEO of Carbon Health, join Julie Yoo, general partner at a16z Bio + Health.
-
IRA, AI Regulation, and the Future with Joe Grogan
In this episode, Joe Grogan, a senior fellow at the Leonard D. Schaeffer Center for Health Policy and Economics and a former senior government official, joins Vijay Pande, founding partner of a16z Bio + Health to discuss all things regulation.
-
Drag & Drop Genome Editing
Today's episode features the cofounders of Tome Biosciences, Rahul Kakkar, CEO of Tome, and John Finn, CSO. They are joined by Jorge Conde, general partner at a16z Bio + Health.
-
AI Jobs to be Done in Life Sciences
We have long believed that AI will fundamentally reshape biotech and healthcare, positioning us at the brink of an AI-driven Industrial Revolution. But when will we see this payoff? Put more boldly, when will the majority of new drugs be designed with AI?
-
Past, Present, and Future of AI with Vijay Pande
Vijay Pande, founding partner of Bio + Health, is joined by Daphne Koller, Andrew Ng, Aviv Regev, and Jakob Uszkoreit. Vijay leads us on a reflective journey through the monumental achievements in AI from the 1980s to today, with a focus on the progress in healthcare and life sciences.
-
The New Drug Delivery Challenge: How Will Cures Reach Patients?
All this to say—it’s time to figure out how to access, pay for, and deliver curative therapies (amongst other high-cost, complex, specialty drugs), at scale. Let’s dive into the specific challenges that need to be surmounted to get this right.
-
Fireside Chat with Sean Duffy
Bio Eats World is now Raising Health! On this first episode of Raising Health, Sean Duffy, cofounder and CEO of Omada Health, joins Vijay Pande, founding partner of Bio + Health.
-
Raising Health
Today, we refocus these efforts and expand on them to give you Raising Health. That’s right, Bio Eats World is now Raising Health. While Bio Eats World had a focus on (bio)technological advancements, Raising Health zooms out, focusing not only on the tech, but also the people building it.
-
Underestimating AI in Healthcare
100% of stock trades used to be made by humans. Today, 80% are made by computer algorithms. AI is about to bring a similar revolution to healthcare. Over the next few decades, at least half of the $4.3 trillion dollar American healthcare industry will be AI-driven.
-
Investing in Tome Biosciences
Tome is launching with over $200 million to advance its PGI platform to focus on in vivo and ex vivo applications, with support from a16z Bio + Health, ARCH, GV, Longwood, Polaris and other leading investors. First up on Tome’s in vivo surgical slate: monogenic diseases of the liver. On the ex vivo cell engineering front, Tome is using PGI to rewire cells to cure common, chronic diseases—an area of great promise—with an initial focus on B-cell driven autoimmune diseases.
-
Generalist Medical AI with Pranav Rajpurkar
Pranav Rajpurkar, PhD, joins Vijay Pande, founding partner of a16z Bio + Health. In this episode, Pranav and Vijay discuss a future with generalist medical AI. This is the idea of a medical AI that isn’t narrowly tailored to one specific task.
-
From Bacteria to Bedside: The Arrival of CRISPR Medicine
Today’s landmark approval by the US Food and Drug Administration of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ EXA-cell, the world’s first CRISPR-based treatment, marks a groundbreaking shift in how we tackle intractable diseases.
-
Big Ideas in Tech for 2024
Smart energy grids. Voice-first companion apps. Programmable medicines. AI tools for kids. We asked over 40 partners across a16z to preview one big idea they believe will drive innovation in the coming year.
-
Gate Unveiling with Jordi Mata-Fink
Jordi Mata-Fink, PhD, cofounder of Gate Bioscience, joins Vineeta Agarwala and Ben Portney of a16z Bio + Health.In this episode, Jordi discusses how he and his cofounders are working to commercialize a novel class of therapeutics, termed "molecular gates."
-
How to Build an AI-Native Health Plan with Mario Schlosser
Mario Schlosser, cofounder, former CEO, and current President of Technology at Oscar Health, joins Julie Yoo of Bio + Health. The conversation explores how AI advancements can revolutionize traditional healthcare models by enhancing efficiency, personalizing care journeys, and integrating real-time data insights.
-
AI: The Teammate Clinicians Need
Our view is that 1) the latest advancements in AI offer a massive enablement opportunity to support our clinicians and 2) this can’t happen without the help of forward-thinking policymakers laying the infrastructure for AI-enabled care.
-
Bridging AI, Ethics, and Consumer Trust with Miriam Vogel
Miriam Vogel, President and CEO of EqualAI, cohost of the podcast In AI we Trust, and Chair to the recently launched National AI Advisory Committee, joins Vijay Pande of Bio + Health.
-
Outclassed: The Battle for Therapeutic Market Share
Each new modality needs to find its platform-disease fit—the diseases it is uniquely suited for. But finding fit has increasingly turned into a fight; many have crowded into the same indications. With an expanding arsenal to treat disease, how will patients, clinicians, and the market determine what tool to use?
-
The Next WebMD: An LLM as Your Front Door to Healthcare
While the Google --> WebMD --> Friend protocol may be a common way to enter into the healthcare system, it is certainly not an optimal one. Most of us are not well-equipped to self-diagnose from a list of possible conditions, and our friends who work in healthcare often don’t have the exact expertise we need.
-
Clinical Copilots: Augmenting Human Care with Suchi Saria
AI trailblazer Suchi Saria, PhD, in conversation with Vijay Pande, sheds light on the winding path that led her to launch Bayesian Health, a bold effort to infuse intelligence into clinical workflows.
-
The Worlds She Sees with Fei-Fei Li
In this candid conversation, Li unfolds her transformation from a young immigrant to an influential figure in AI. The conversation explores the birth of ImageNet, a pivotal step that bridged the gap between visual intelligence and accessible AI technology.
-
Investing in Gate Bioscience
While most small molecule drugs bind and inhibit the disease-causing activity of their (typically intracellular) protein targets, Gate Bio instead attacks harmful extracellular proteins by eliminating them at their very root: right where they are produced and secreted from the cell.
-
Supercharging Discovery with Evan Feinberg
Together, they talk about how Evan’s work in the lab (ironically, Vijay's lab at Stanford!) translated to the creation of Genesis, which is tackling the problem of drug discovery through AI. They also discuss how the Genesis team is building specifically to carry on work at the intersection of ML, biotech, and chemistry.
-
Evolving Biotechnologies with Olga Troyanskaya
Olga Troyanskaya, PhD, a professor in the department of computer science at Princeton and Deputy Director for Genomics at the Flatiron Institute's Center for Computational Biology, joins Vijay Pande, founding partner of a16z Bio + Health.
-
CMO vs. CPO with Peter Shalek and Reena Pande
As Julie mentions during the episode, there’s international relations, and then there’s CMO/CPO relations. Peter and Reena talk about working together to improve their relationship and the outcomes of their teams, and they get granular about what worked and what didn’t.
-
Commercializing AI in Healthcare: The Enterprise Buyer Perspective
At the end of the day, even the best AI models will fail if they don’t figure out a way to achieve broad distribution and profitable monetization, so it’s important to understand the psyche of the buyers and decision makers who will determine the fate of your products.
![](https://d1lamhf6l6yk6d.cloudfront.net/uploads/2024/05/Bio_CTA_BG_Desktop-2048x396.jpg)
![](https://d1lamhf6l6yk6d.cloudfront.net/uploads/2024/05/Bio_CTA_BG_Mobile-1024x533.jpg)
![](https://d1lamhf6l6yk6d.cloudfront.net/uploads/2024/05/Bio_CTA_Foreground_IMG-1024x498.png)
Raising
Health™
Our top-ranked podcast exploring the real challenges and enormous opportunities facing entrepreneurs who are building the future of health.